Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

NCT06783790 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

AML (Acute Myelogenous Leukemia)

Interventions

DRUG: Avapritinib, azacitidine, Venetoclax

Sponsor

Institute of Hematology & Blood Diseases Hospital, China